Pear Therapeutics Past Earnings Performance
Past criteria checks 0/6
Pear Therapeutics's earnings have been declining at an average annual rate of -15.9%, while the Healthcare Services industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 201.7% per year.
Key information
-15.9%
Earnings growth rate
5.3%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 201.7% |
| Return on equity | -246.8% |
| Net Margin | -594.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Aug 18Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic
Aug 03Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
May 21Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Apr 04Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Jan 10Revenue & Expenses Breakdown
How Pear Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 13 | -75 | 78 | 46 |
| 30 Sep 22 | 11 | -30 | 82 | 48 |
| 30 Jun 22 | 9 | -31 | 82 | 48 |
| 31 Mar 22 | 7 | -65 | 76 | 43 |
| 31 Dec 21 | 4 | -65 | 68 | 37 |
| 30 Sep 21 | 3 | -143 | 68 | 31 |
| 30 Jun 21 | 2 | -131 | 62 | 28 |
| 31 Mar 21 | 9 | -114 | 59 | 27 |
| 31 Dec 20 | 9 | -108 | 56 | 28 |
| 31 Dec 19 | 33 | -9 | 27 | 36 |
Quality Earnings: PEAR.Q is currently unprofitable.
Growing Profit Margin: PEAR.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PEAR.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PEAR.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEAR.Q is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (9.8%).
Return on Equity
High ROE: PEAR.Q has a negative Return on Equity (-246.82%), as it is currently unprofitable.